CeriBell (CBLL) Stock Analysis & Winston Score

CeriBell makes a medical device that monitors brain activity in critically ill patients. Its main product is a rapid-setup EEG (electroencephalogram) headset that can be applied quickly by nurses or other hospital staff — not just specialized technicians. The device is designed for use in hospital intensive care units (ICUs), where doctors need to detect dangerous brain conditions like seizures in patients who may not show obvious symptoms. CeriBell earns revenue by selling its headsets and disposable sensor components to hospitals, creating a recurring revenue stream each time the device is used on a new patient. The company operates primarily in the United States and, with an 88.9% gross margin, benefits from a high-margin consumables model similar to a "razor and blade" approach. However, it is spending heavily to grow, reflected in a deeply negative operating margin. The key growth driver is expanding adoption across more ICUs, while the main risk is convincing hospitals to replace traditional EEG workflows with a newer, less-established system.